Dr Elena Zamagni speaks to ecancer about a study she presented at ASH 2024 looking at teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide alone in newly diagnosed multiple myeloma (NDMM) as maintenance therapy following autologous stem cell transplantation (ASCT).

She reports that the combination and teclistamab alone can both be safely administered with manageable toxicities.

Dr Zamagni also highlights the efficacy results with 100% of patients upgrading their response during maintenance up to a complete response.